Traditionally, generating a monoclonal antibody via hybridoma might take 3–6 months (immunize mouse, fuse cells, screen clones, subclone, produce ascites or culture supernatant). Phage display might take a similar time to panning, plus conversion of hits to IgG and further maturation. In contrast, Biointron’s AbDrop™ can yield antibody sequences in a matter of days after immunization, and confirmed hits in about a month. This “days to hits” capability can shave off months from early discovery, which is particularly advantageous if the target is time-sensitive or if a company wants to quickly explore multiple target antigens in parallel.
Biointron’s infrastructure is built for parallel processing on a massive scale, as demonstrated by hundreds of antibodies produced in weeks. This means projects can maintain breadth longer – exploring more candidates before narrowing down – which statistically increases the chance of finding an optimal therapeutic candidate, being less likely to miss the needle in the haystack.
Beyond discovery and production, Biointron also offers services like Affinity Maturation, Antibody Humanization, and VHH discovery. This means if a candidate does need improvement, Biointron can handle that in-house. For instance, if an antibody needs slightly better binding, their affinity maturation service can do targeted mutagenesis in CDR regions and screen variants. If a client has a mouse or rabbit antibody, Biointron’s humanization service could adapt it to a human framework with minimal immunogenicity.
A potential pain point in drug development is when a promising lead from research fails in manufacturing – e.g., yields are too low, or the protein aggregates at scale. By involving production experts early, if we discover or express an antibody and notice any red flags such as poor expression or stability, we can alert the client or make modifications (e.g. sequence optimization, different isotype formats, etc.). Also, using the same CHO cells for small-scale and large-scale (different volumes) means a smoother scale-up curve. Biointron’s experience with both HEK293 and CHO for expression ensures that when the time comes to scale, we can replicate the process in the appropriate system.
Some technology platforms for antibody discovery (especially those involving transgenic animals or certain display libraries) come with future royalties or licensing fees if the antibody becomes a product. With Biointron, clients fully own the antibodies discovered and owe nothing beyond the service fees. This is a significant business consideration. For biopharma companies, this can be a deciding factor to protect long-term asset value.
Biointron offers services at market-competitive rates due to our high degree of automation and scale. Traditional in-house efforts can become more costly when factoring in personnel, equipment, and opportunity cost of time. Outsourcing to a group that can do it faster and perhaps in a more automated fashion may be better suited.
With over 2,000 companies across the world served, Biointron has encountered a wide array of targets and project types. This broad experience can be invaluable when unexpected challenges arise, such as an antibody that is tough to express or a complex bispecific format. Our collaborations mean we are familiar with the documentation and quality needed research-grade tasks.
At Biointron, we are dedicated to accelerating antibody discovery, optimization, and production. Our team of experts can provide customized solutions that meet your specific research needs, including HTP Recombinant Antibody Production, Bispecific Antibody Production, Large Scale Antibody Production, and Afucosylated Antibody Expression. Contact us to learn more about our services and how we can help accelerate your research and drug development projects.
DOI: 10.3389/fbioe.2022.856049Antibodies have become essential tools for the diagnosis and treatment of numerous human diseases. However, non-human antibodies, such as those derived from murine sources, often provoke human anti-mouse antibody (HAMA) responses. This immunogenicity leads to rapid clea
In therapeutic antibody development, achieving high-affinity antigen binding is central to improving drug efficacy, durability, and safety.Biointron’s High-Throughput Fully Human Antibody Discovery service is designed to meet this need by integrating advanced screening and engineering technol
I. Introduction to Hybridoma TechnologyHybridoma technology, developed by Köhler and Milstein in 1975, is a foundational method for producing monoclonal antibodies (mAbs). The approach involves fusing antibody-producing B lymphocytes with immortal myeloma cells to form hybridoma cells. These hybrid
Introduction to Monoclonal Antibody Discovery Monoclonal antibodies (mAbs) are one of the most successful classes of biologic drugs on the global pharmaceutical market. Since the approval of Orthoclone OKT3 in 1986, over 100 mAbs have been approved by the U.S. FDA for indications incl
ScientistとScience Exchangeとのご利用可能です。
